What We're Reading: Page 376
Industry reads hand-picked by our editors
Dec 05, 2014
-
Reuters
Whistleblower: Sanofi, ex-CEO Viehbacher paid out $34M in kickback scheme
-
-
FDA OKs Amgen's Blincyto to treat rare form of acute lymphoblastic leukemia
-
Confirmed: GSK to chop 900 jobs, mostly in North Carolina, in massive reorg
-
-
Mice infused with human brain cells shed light on cognitive function
-
-
Beyond ABC: FDA finalizes labeling rules for pregnant, lactating women
-
-
Actavis to lay off 200 workers in California
-
Dec 04, 2014
-
Security firm: Hackers trying to manipulate global markets by stealing pharma emails
-
-
A $945 million breakup: J&J, Astellas call off major rheumatoid arthritis deal
-
-
Promising Biogen Alzheimer's drug leapfrogs from phase I to phase III
-
-
-
Puma Biotech plummets in after hours trading after delaying breast cancer NDA
-
-
Patent cliff ahead: Otsuka to buy Avanir for $3.5B and a slate of new products
Dec 03, 2014
-
-
Mylan strikes deal to make Gilead's HIV drugs more accessible to poor nations
-
-
Done deal: Pfizer completes acquistion of Baxter's vaccines
-
Why BMS is getting ready to slash up to 1,000 jobs in China
-
-
Meet the healthcare and pharma industry vet who will be Teva's next chairman
-
-
-
Despite deaths, Italian regulators declare Novartis flu vaccine safe—for now
Dec 02, 2014
-
Job cuts ahead: GSK plans US workforce restructuring
-
-
-
EU green lights BI's Vargatef for advanced lung cancer
-
Report: China considering large-scale eradication of drug price caps
-
-
Glaxo/NIH Ebola vaccine elicits immune response in human trials
-
The key to successful clinical trial recruitment? Patient empowerment
-
-
Dec 01, 2014
-
Trouble for J&J? Amgen/AZ plaque psoriasis drug bests Stelara in phase III
-
-
Takeda US CEO leaving after 22 years
-
-
Lilly’s once-weekly diabetes drug approved in EU
-
-
-
FDA: No decision on Novartis' troubled panobinostat for 3 months
-
-
Generic drug price hikes move Congress to consider consumer relief measures
Nov 26, 2014
-
-
Top UK fund manager to launch major new biotech fund in 2015
-
3 compounding pharmacies sue Express Scripts over blocked coverage
-
Lundbeck CEO resigns after serious conduct breaches
-
-
-
Novartis scientist who fabricated data fired and banned from receiving funding
-
-
In search of new opportunities, Bayer considers selling $2.5B diabetes unit
-
Nov 25, 2014
-
BioMarin makes $840M gamble, buys Prosensa and its orphan drugs
-
-
UK life sciences minister: Hospitals must aid in clinical trial process
-
-
Hep C wars heat up as AbbVie scores likely EU approval for Harvoni challenger
-
-
Merck, NewLink strike exclusive deal to scale up Ebola vaccine production
-
-
-
EU regulators weigh in on hotly debated testosterone, heart attack link
Previous
